2015 American Transplant Congress
IFNγ Is Required for nTreg Afferent Lymphatic Migration
Surgery, University of Maryland, Baltimore, MD.
Background: Natural Treg (nTreg) must migrate from graft to draining lymph node (LN) to prolong islet allograft survival, and we previously showed that the transcription…2015 American Transplant Congress
Diabetes Mellitus Predicts Outcome in Obesity After Kidney Transplantation
Obesity has been associated with an increased risk of graft loss and death after kidney transplantation. The role of cellular immunity in obese kidney transplant…2015 American Transplant Congress
Graft Outcome Disparity in a Single Renal Transplant Center Based on Recipient Geographic Origin
University of Toledo Medical Center, Toledo, OH.
PURPOSE: The disparity in access to organs for kidney transplantation has led to inter-state “transplant tourism.” Our objective was to determine if recipients traveling over…2015 American Transplant Congress
CPRA Values Are Substantially Increased for Some Candidates Subsequent to Inclusion of Unacceptable C-locus (UA-C) Antigens While Listing Practices Remain Unchanged
1UNOS, Richmond; 2Emory University Hospital, Atlanta; 3Stanford University, Palo Alto.
Background: CPRA is the % of deceased donors expected to have one or more UAs with a given candidate. Prior to 12/5/13, candidates with UA-C…2015 American Transplant Congress
TGR5 Regulates Innate Immune Responses in Mouse Liver Ischemia-Reperfusion Injury Through NRF2/HO-1 Signaling Pathway
The G-Protein-Coupled Bile Acid Receptor (TGR5), also called Gpbar1 or GPBA, is a G-protein coupled plasma membrane receptor for Bile acids (BAs) which is expressed…2015 American Transplant Congress
Clusterin-Regulated Transcriptome in the Kidney During Ischemia-Reperfusion
BACKGROUND: Ischemia-reperfusion injury (IRI) has a significate impact on both short and long-term transplant outcomes, and is a major cause of delayed graft function in…2015 American Transplant Congress
24 Month Post Transplantation Follow Up of the Certitem Trial
Background: CERTITEM has evaluated the effect of everolimus/calcineurin inhibitors free (CNI free) on fibrosis progression and results have been reported at 12 months (M12). Data…2015 American Transplant Congress
Increasing Tacrolimus Exposure to Minumize Chronic Rejection: How Can We Do It? What Are the Risks?
Background: Recent studies suggest that increased tacrolimus (TAC) exposure may help prevent production of donor specific HLA antibodies (DSAs) that mediate chronic rejection of renal…2015 American Transplant Congress
Outcomes of Kidney Transplant Recipients Minimally Immunosuppressed: A Cohort Study Analysis
Background: Renal transplantation is the treatment of choice for endstage renal disease. Nevertheless, it involves immunosuppressive treatments with Serious Adverse Events (SAE) such as infections…2015 American Transplant Congress
Tacrolimus for the Treatment of Refractory Biopsy-Proven Acute Cellular Rejection in Patients on Belatacept-Based, CNI- and Steroid-Free Immunosuppression Regimens
1Univ of Cincinnati, Cincinnati; 2The Christ Hospital, Cincinnati.
Background: Tacrolimus (TAC) is effective as rescue treatment (tx) in renal transplant patients (pts) on cyclosporine-based immunosuppression (IS) who have recurrent or resistant acute rejection…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 170
- Next Page »